Dear Niurys,
It would be down to distributional assumptions in that case.
For example if you have a very strong predictor (covariate) of either
elimination or absorption rate (but not both) - data could be informative to
discriminate between flip-flop or not.
Had your therapeutic been IgG
Dear nmusers,
I'm working on the population PK of a therapeutic peptide candidate for
rheumatoid arthritis. Three dose levels of the peptide were administered as
a single subcutaneous injection.
We have some limitations, for instance, the dataset is very sparse and is
lacking in the information
AI-powered modeling approaches to support the development of new therapies for
autoimmune diseases
Philippe Moingeon, PhD, MBA, Head of Immuno-inflammation Portfolio, Servier
Wednesday, September 21, 2022, 9:00 to 10:00 am PDT
Register for free at
